,16 In the absence of direct head-to-head comparisons between PD-(L)1 inhibitor monotherapy and chemo-immunotherapy in patients with advanced NSCLC and a PD-L1 TPS greater than or equal to 50% or greater than or equal to 90%, our data indicate that PD-1 inhibitor monotherapy with cemiplimab or pembrolizumab will continue to represent an appropriate safe and effective therapeutic standard option in patients with very high PD-L1 expression. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.